'
RPG
Life sciences hosted a conference call on April 29, 2025. In the conference call,
the company was represented by Mr Vishal shah- CFO and Mr Yugal Sikri- Managing
director.
Key takeaways of the call
In Q4 FY25, the overall performance of the company
continued to be strong. Revenue and PBT before exceptional items grew by 13%
and 41% respectively YoY.
The company’s first growth engine, Domestic Formulations
business, has continued to register profitable and healthy growth consistently
higher than the market supported by its five-pillar strategy, of building
brands, portfolios and therapies; increasing sales force productivity and
nurturing strategic business assets.
The company is progressing well in shaping its
International Formulations and API businesses to emerge as second and third
growth engines by way of modernization of both API and Formulations plants,
setti...
Pleaselogin & subscribe to view the full report.
More Reports
-
(05-Feb-2025)
Castrol India
Expects EBITDA margin of 22%-25% for CY25
-
(10-Feb-2023)
Deepak Nitrite
Plans capex of about Rs 1500 crore for FY23 and FY24
-
(09-Feb-2023)
Mayur Uniquoters
Targets revenue of Rs 1000 crore in FY24
-
(31-Jan-2023)
Tega industries
Capex plan is US$ 30-32 million for next three years
|
|